An oncocytic neoplasm is not automatically cancer. It is a growth made up of a specific type of cell, called an oncocyte, that is packed with an unusually high number of mitochondria (the energy-producing structures inside cells). These tumors can be completely benign, potentially malignant, or fully cancerous, depending on where they grow and what a pathologist finds under the microscope. The critical distinction between a harmless oncocytic tumor and a cancerous one comes down to whether the tumor has invaded surrounding tissue, blood vessels, or its own outer capsule.
What Makes a Cell “Oncocytic”
Oncocytic cells were first described in 1931 as cells with a granular, pink-staining interior caused by a massive buildup of mitochondria. This mitochondrial accumulation is the defining feature. It gives the cells a distinctive appearance under the microscope, but on its own it says nothing about whether the tumor is dangerous. Oncocytic cells can show up in the thyroid, kidneys, adrenal glands, salivary glands, and other organs. The same type of cell can form a harmless lump in one person and an aggressive cancer in another.
How Doctors Tell Benign From Malignant
The frustrating reality of oncocytic neoplasms is that they often look the same on the surface. A needle biopsy, the usual first step in evaluating a suspicious lump, frequently cannot tell a benign oncocytic tumor from a cancerous one. That’s because the individual cells may appear identical in both cases. Common signs pathologists rely on for other tumors, like unusual cell shapes or irregular architecture, show up in both benign and malignant oncocytic growths.
The definitive answer almost always requires surgical removal and a full examination of the tissue. Pathologists look for specific invasion patterns: has the tumor broken through its capsule? Has it grown into blood vessels? Has it spread into nearby nerves or soft tissue? The presence of any of these features is what separates cancer from a benign growth. Additional markers like high rates of cell division and certain genetic changes (particularly mutations in the TP53 gene, which is a tumor suppressor) are associated with more aggressive disease.
Oncocytic Tumors in the Thyroid
The thyroid is one of the most common sites for oncocytic neoplasms. You may hear these called Hürthle cell tumors. A benign version is a Hürthle cell adenoma; the cancerous version is a Hürthle cell carcinoma, now formally classified as oncocytic thyroid carcinoma. The distinction between the two rests entirely on whether the tumor has invaded its capsule, blood vessels, or both. A needle biopsy cannot make this call, which is why surgery is typically needed to reach a diagnosis.
When oncocytic thyroid carcinoma is confirmed, the prognosis is generally favorable. The overall five-year survival rate across all stages is approximately 98.5%. That said, outcomes vary with tumor stage and whether the cancer has spread. Research has found that oncocytic thyroid carcinomas carry a higher prevalence of TP53 and TERT promoter mutations compared to other follicular thyroid cancers. Both of these genetic markers are linked to more invasive, aggressive behavior. Patients whose tumors harbor TP53 mutations have consistently been diagnosed with aggressive disease.
Oncocytic Tumors in the Kidney
In the kidney, the classic benign oncocytic tumor is called a renal oncocytoma. It is one of the most common benign kidney tumors found after surgery. The challenge is that renal oncocytomas look strikingly similar to chromophobe renal cell carcinoma, a type of kidney cancer, both on imaging and on biopsy. Both tumor types even share the same immunohistochemical staining pattern in many cases.
In a recent study of 198 kidney biopsies showing oncocytic features, 56% turned out to be benign oncocytomas, while 28% were chromophobe renal cell carcinomas. The overall risk of malignancy across all oncocytic kidney tumors was 35%, meaning roughly two out of three were benign. When the initial biopsy was categorized as benign, only 2% ultimately proved to be cancerous. Newer imaging techniques that measure how quickly a tumor absorbs contrast dye on a CT scan are improving the ability to distinguish these tumors without surgery, achieving sensitivity above 93% in some studies.
Oncocytic Tumors in the Salivary Glands
Salivary gland oncocytic tumors, most commonly found in the parotid gland, are another area where the benign-versus-malignant question creates diagnostic difficulty. Oncocytic carcinoma of the salivary glands is rare and typically presents as a slow-growing, painless lump that initially looks benign. Warning signs that suggest cancer include rapid growth, facial nerve problems (like weakness or paralysis on one side of the face), the mass becoming fixed to surrounding structures, or swollen lymph nodes in the neck.
Needle biopsies of salivary oncocytic lesions have limited accuracy for subclassification. In one study of 80 salivary cases with oncocytic features, only about 54% of needle biopsy diagnoses matched the final surgical pathology exactly. Among seven cases initially called “oncocytic neoplasia” on biopsy, three (43%) turned out to be malignant on final tissue examination. Histopathology remains the gold standard, with pathologists looking for cell irregularity, increased cell division, capsular or vascular invasion, and growth into nerves or surrounding tissue.
Oncocytic Tumors in the Adrenal Glands
Adrenal oncocytomas are uncommon. They use a separate grading system called the Lin-Weiss-Bisceglia criteria because the standard scoring system for adrenal cancers does not work well for oncocytic tumors. This system divides features into major criteria (high rates of cell division, abnormal cell division patterns, or invasion into veins) and minor criteria (tumor larger than 10 cm or heavier than 200 grams, tissue death within the tumor, or invasion of the capsule or small blood channels). Any single major criterion classifies the tumor as malignant. Minor criteria alone place it in an uncertain category. If none of these features are present, the tumor is considered benign.
Why the Diagnosis Takes Time
If you have been told you have an oncocytic neoplasm, the wait for a definitive answer can feel long. The core reason is that the individual cells in benign and malignant oncocytic tumors look nearly identical. A needle biopsy samples only a small number of cells and cannot assess the invasion patterns that define cancer. In most cases, the tumor needs to be surgically removed and examined in its entirety before a pathologist can say with confidence whether it is benign or malignant. Additional testing, including specialized staining and sometimes genetic analysis, may add days or weeks to the process. This is not a sign that something has gone wrong. It reflects the genuinely difficult nature of these tumors.
The bottom line: an oncocytic neoplasm is a tumor defined by its cell type, not by whether it is cancerous. The majority of oncocytic tumors are benign, but a meaningful percentage are malignant. The specific organ involved, the presence of invasion into surrounding structures, and certain genetic markers together determine whether an individual tumor is cancer and how it is likely to behave.